Study title: Comparison of the efficacy, safety and onset of action of mizolastine, cetirizine and placebo in the management of seasonal allergic rhinoconjonctivitis. Sabbah A et al (MIZOCET group). (Ann Allerg Asthm Immunol 1999 ; 83: 319-325) Publication 12 in CES DOSFILIRF-CES0386-EN-E01 - N. BLAY - 30/06/2005 Comparison of the efficacy, safety and onset of action of mizolastine, cetirizine and placebo in the management of seasonal allergic rhinoconjonctivitis. Sabbah A et al (MIZOCET group). (Ann Allerg Asthm Immunol 1999 ; 83: 319-325) Publication 12 in CES DOSFILIRF-CES0386-EN-E01 - N. BLAY - 30/06/2005
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Immune System Diseases [C20] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: MIZOLASTINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |